AJMC® in the Press, June 7, 2019

June 7, 2019
AJMC Staff
AJMC Staff

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care® (AJMC®)’s article “Seema Verma Envisions a US Health System That Shares Data, Is Truly Value-Based,” in which CMS Administrator Seema Verma told AJMC® in written responses that our current healthcare system is complex, opaque, and difficult to navigate for patients. According to Verma, empowering patients starts with giving them access to their own personal health data.

OBR Oncology’s Tuesday newsfeed included AJMC®’s coverage of the American Society of Clinical Oncology (ASCO) Annual Meeting 2019. The article “How Real-World Data Can Impact NSCLC Treatment” covered several abstracts from the meeting that focused on using real-world data to advance research and cancer care in non—small cell lung cancer. The article “Oncology Reimbursement Reform Leaves Stakeholders With More Questions Than Answers” covered a session in which oncologists and representatives from UnitedHealthcare and the Center for Medicare and Medicaid Innovation (CMMI) took the stage to discuss oncology reimbursement reform and whether there are changes on the horizon for the promotion of higher value care.

Wednesday’s newsfeed included the AJMC® article “COA Urges Delay in Downside Risk Deadline for OCM,” which covered a letter from the Community Oncology Alliance to CMMI urging a delay in the October 2019 deadline for practices in the Oncology Care Model that have not yet achieved shared savings payments to make a decision on 2-sided risk.

Thursday's newsfeed included an article from AJMC®’s sister site The Center for Biosimilars®. The article, “Amgen’s Trastuzumab Biosimilar, Kanjiti, Clinically Similar to Herceptin in Cardiac Safety,” covered findings presented at ASCO that surrounded the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980, versus the reference trastuzumab, Herceptin.